Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

CASC 4.20 +0.08 (1.94%)
price chart
Here's Why Cascadian Therapeutics Inc (USA) (CASC) Shares Tumble 11%
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock and Series E convertible preferred stock in concurrent but separate underwritten public offerings.
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that its board of directors has approved a plan for a reverse split of the Company's common stock to increase its share price and reduce the number of authorized and outstanding shares.
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Cowen Dives in on Cascadian Therapeutics Inc (USA) (CASC) Following HER2CLIMB ...
Cowen analyst Boris Peaker weighed in on Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) with a few insights after the company announced that following a recent meeting with the FDA and discussions with the Company's external Steering Committee, ...
Sell-side is Weighing in on Cascadian Therapeutics Inc (USA) (NYSE:CASC) Earnings
Investors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability.
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Receives ONT-380 ...
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug ...
Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care ...
SEATTLE, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cowen and Company 37th Annual Health Care Conference ...
Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
SEATTLE, March 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today reported financial results for the fourth quarter and full year ended December 31, 2016.
Cascadian Therapeutics reports 4Q loss  Yahoo Finance
Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib ...
SEATTLE, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names ...
Cascadian Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare ...
20, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Julie Eastland, Chief Financial Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare ...